Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Using gene expression analyses of cancer-resistant differentiated muscle cells, Keckesovaet al. identify a mitochondrial protein, lactamase β (LACTB), that affects lipid metabolism and can induce differentiation and suppress proliferation of breast cancer cells in vitro and in vivo.
Boireet al. describe a mechanism by which cancer cells can survive and grow in the leptomeninges of the brain by upregulating complement component 3 (C3) to disrupt blood–cerebrospinal fluid barrier function, allowing entry of growth-promoting factors.
The human microbiota influences a whole range of physiological functions. In this Review, Roy and Trinchieri discuss our current understanding of how the gut microbiota modulates responses to cancer therapy as well as mediating susceptibility to toxic side effects.
Insights into the effects of targeted therapies, conventional chemotherapy and radiation therapy, on the induction of antitumour immunity will help to advance the design of combination strategies that increase the rate of complete and durable clinical responses in patients.
Deregulation of fibroblast growth factor (FGF) signalling is observed in several types of cancer, which makes this pathway a highly promising potential therapeutic target. However, aberrant FGF receptor (FGFR) signalling can be challenging. In this Review, Babinaet al. discuss the differences between diverse mechanisms of oncogenic activation of FGFR, and the factors that determine response and resistance to FGFR targeting.
